
Feature|Articles|December 23, 2025
- December 2025
- Volume 19
- Issue 4
Cancer Care and Education in the Era of Precision Oncology
Author(s)Linda Childers
Fact checked by: Bridget Hoyt, Tracy Ann Politowicz
Oncology nurses and APPs are key players in patient education on precision medicine.
Advertisement
Advertisement
In the era of precision oncology, nurses and advanced practice providers (APPs) do far more than manage chemotherapy or monitor adverse effects (AEs). Today’s cancer care requires a strong understanding of genetics and genomics, as these fields now drive how cancers are detected, treated, and even prevented. Genomic testing is routinely used to identify inherited cancer risks, guide screening strategies, and match patients with targeted therapies.
Related to this article

Oncology NPs and PAs are key to closing workforce gaps. Here’s how generalist, specialist, and hybrid APP models improve access and outcomes.

Perioperative durvalumab with enfortumab vedotin given only before cystectomy cut the risk of an EFS event by 49% in the phase 3 VOLGA trial.

The PCR-based tissue assay can now identify patients with MSI-high solid tumors who may be candidates for pembrolizumab.

The oral CSF-1R inhibitor produced a 54% response rate vs 3% with placebo at week 25 in the phase 3 MANEUVER trial.

FDA grants accelerated approval to amivantamab and hyaluronidase-lpuj for recurrent or metastatic head and neck squamous cell carcinoma.

A 3-minute video and quick-reference list of October's 7 FDA cancer approvals, with the biomarker and monitoring points nurses need for each.

A 5-decade SEER analysis found 5-year survival in young patients rose from 60% to 90%, yet non-Hispanic Black patients fared worst across cancers.
Advertisement
Advertisement

